Millions of individuals using weight-loss injections are being cautioned about potential long-term harm if they fail to adjust their eating and exercise routines during their weight loss journey. Experts emphasize the importance of providing proper guidance to users to avoid risks of malnutrition, muscle loss, and reduced bone density if they solely rely on the injections. A consensus statement issued at a major European obesity conference in Istanbul highlighted significant concerns regarding the use of GLP-1 drugs without incorporating appropriate diet and physical activity.
The statement, co-authored by 26 renowned obesity experts, warned that individuals could face malnutrition if they persist with unhealthy eating habits and simply reduce their intake. It stressed the necessity for injection users to consume adequate high-quality protein and engage in weight-bearing exercises, as research presented at the conference suggested that a substantial portion of weight lost through injections could be non-fat mass, primarily involving muscle and bone density.
Discontinuing the injections often leads to weight regain, without the recovery of muscle or bone. Co-author Dr. Laurence Dobbie, a population health specialist at King’s College London, emphasized the importance of prioritizing nutrient-dense foods to maintain dietary quality, ensuring the intake of suitable protein, fiber, and fluids.
In terms of physical activity, Dr. Dobbie recommended prioritizing resistance training with two to three sessions per week as the primary component, followed by 150 to 300 minutes weekly of aerobic exercise, emphasizing that any form of movement is beneficial. This advice for a more balanced approach comes as some individuals may need to remain on the injections indefinitely to prevent weight regain due to potential neurological issues.
Professor Louis Aronne, a pioneering figure at Weill Cornell Medicine in New York, explained that overeating processed, high-calorie foods leading to obesity can cause lasting brain damage, making it challenging for patients to feel satiated even after losing weight. The injections, soon to be available in pill form, act by mimicking a hormone called GLP-1, inducing a sense of fullness sooner.
With approximately 2.5 million Britons using these injections, primarily through costly private prescriptions, concerns persist about how to sustain weight loss in the long term and mitigate potential adverse effects. The availability of essential support from the NHS is questioned, as some individuals resort to obtaining cheap weight loss drugs from unauthorized online sources. Professor Jason Halford, former president of the European Association for the Study of Obesity, highlighted the need for a healthcare system capable of effectively supporting weight loss initiatives.
The NHS assured that weight loss medications play a crucial role in promoting healthier lifestyles, emphasizing access based on clinical necessity and ongoing efforts to expand safe opportunities for more individuals to benefit from weight loss interventions. Prof. Aronne, a long-time researcher in appetite regulation, envisions a future where weight loss pills could be used preventatively in healthy young adults to prevent obesity, similar to preventive measures taken with hypertension medications.
Both Prof. Aronne and Prof. Torekov, recipients of substantial research funding from pharmaceutical companies manufacturing GLP-1 drugs, acknowledge the existing concerns surrounding the widespread use of these medications.